Teva Pharmaceutical Receives FDA Approval for Innovative Schizophrenia Drug
Translated & summarized from Ice by baba
Teva Pharmaceuticals received U.S. FDA approval for WELTRUZA™, a new monthly injectable drug for adult schizophrenia. The approval, based on the SOLARIS study, boosts Teva's stock and supports its strategy of focusing on innovative drugs. The company anticipates annual sales of 1.5 to 2 billion shekels from this treatment, which uses SteadyTeq™ technology and does not require post-injection monitoring.
The story in 5 lines · by baba
- Teva Pharmaceuticals received U.S. FDA approval for its new schizophrenia drug, WELTRUZA™.
- The monthly subcutaneous injection treats adult schizophrenia and is based on olanzapine.
- Teva's stock rose 3% following the FDA approval announcement.
- The company projects annual sales for WELTRUZA™ to reach 1.5 to 2 billion shekels.
- The drug utilizes SteadyTeq™ technology and does not require post-injection monitoring.
Israeli pharmaceutical company Teva announced on Friday that it has received official approval from the U.S. Food and Drug Administration (FDA) for its new drug WELTRUZA™ (olanzapine). This medication is a monthly subcutaneous injection designed for the treatment of adult schizophrenia. The approval marks a significant milestone for Teva, reinforcing its strategic shift towards developing innovative, proprietary drugs rather than focusing solely on generics. The company's stock saw a 3% increase following the announcement.
Teva presented an optimistic forecast to investors, projecting that the long-acting injectable treatment for adult schizophrenia could generate annual sales of 1.5 to 2 billion shekels. This development aligns with the company's broader "Pivot to Growth" strategy, as discussed by Chris Fox, Teva's US Commercial SVP and Innovative Franchise Lead. WELTRUZA is highlighted as the first and only olanzapine-based long-acting injectable (LAI) administered via a monthly subcutaneous injection.
The drug's administration does not require loading doses, oral adjuncts, or post-injection medical monitoring. It utilizes SteadyTeq™ technology to ensure a stable, controlled, and prolonged release of olanzapine. The medication is expected to be available in the U.S. within the coming weeks.
The FDA's approval is based on the results of the Phase 3 SOLARIS study. This trial demonstrated improvements in schizophrenia symptoms, a significant reduction in illness severity, and enhanced personal and social functioning among patients. Side effects were reported to be similar to those of the oral form of the medication. The Chief Medical Officer, Teva's Chief Medical Officer, noted that eliminating the need for post-injection monitoring removes a substantial barrier to treatment and facilitates care for individuals living with this complex condition.
Mentioned
